Beijing SL Pharmaceutical Co., Ltd. (002038)
Market Closed
25 Jul, 06:57
XSHE XSHE Primary ¥
7. 97
-0.09
-1.12%
¥
8.27B Market Cap
- P/E Ratio
0.08% Div Yield
26,347,027 Volume
- Eps
¥ 8.06
Previous Close Day Range
7.79 8.14
Year Range
5.98 8.71
Want to track 002038 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
002038 closed today lower at ¥7.97, a decrease of 1.12% from yesterday's close, completing a monthly increase of or ¥7.97. Over the past 12 months, 002038 stock gained .
002038 pays dividends to its shareholders, with the most recent payment made on Jul 04, 2025. The next estimated payment will be in In 11 months on Jul 04, 2026 for a total of ¥0.02.
The last earnings report, released on Oct 26, 2024, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
Beijing SL Pharmaceutical Co., Ltd. has completed 1 stock splits, with the recent split occurring on Jul 04, 2019.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
002038 Chart
Beijing SL Pharmaceutical Co., Ltd. Dividends
| 002038 In 11 months Estimated | Annual | ¥0.02 Per Share |
| 002038 3 weeks ago Paid | Annual | ¥0.02 Per Share |
| 002038 4 Jul 2024 | Other | ¥0.15 Per Share |
| 002038 28 Jun 2023 | Other | ¥0.1 Per Share |
| 002038 29 Jun 2022 | Other | ¥0.1 Per Share |
| 002038 7 Jul 2021 | Other | ¥0.1 Per Share |
Beijing SL Pharmaceutical Co., Ltd. Earnings
| 26 Oct 2024 Date | | - Cons. EPS | - EPS |
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 23 May 2024 Date | | - Cons. EPS | 0.07 EPS |
| 24 Apr 2024 Date | | - Cons. EPS | 0.07 EPS |
| 26 Oct 2023 Date | | - Cons. EPS | 0 EPS |
| 002038 In 11 months Estimated | Annual | ¥0.02 Per Share |
| 002038 3 weeks ago Paid | Annual | ¥0.02 Per Share |
| 002038 4 Jul 2024 | Other | ¥0.15 Per Share |
| 002038 28 Jun 2023 | Other | ¥0.1 Per Share |
| 002038 29 Jun 2022 | Other | ¥0.1 Per Share |
| 002038 7 Jul 2021 | Other | ¥0.1 Per Share |
| 26 Oct 2024 Date | | - Cons. EPS | - EPS |
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 23 May 2024 Date | | - Cons. EPS | 0.07 EPS |
| 24 Apr 2024 Date | | - Cons. EPS | 0.07 EPS |
| 26 Oct 2023 Date | | - Cons. EPS | 0 EPS |
Beijing SL Pharmaceutical Co., Ltd. (002038) FAQ
What is the stock price today?
The current price is ¥7.97.
On which exchange is it traded?
Beijing SL Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 002038.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.08%.
What is its market cap?
As of today, the market cap is 8.27B.
Has Beijing SL Pharmaceutical Co., Ltd. ever had a stock split?
Beijing SL Pharmaceutical Co., Ltd. had 1 splits and the recent split was on Jul 04, 2019.
Beijing SL Pharmaceutical Co., Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. Mingbo Xu Ph.D. CEO | XSHE Exchange | CNE000001L31 ISIN |
| CN Country | 889 Employees | - Last Dividend | 4 Jul 2019 Last Split | 25 Aug 2004 IPO Date |
Overview
Beijing SL Pharmaceutical Co., Ltd., established in 1994 under its former name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd., and underwent a name change in 1998 to its current designation. Operating from the heart of Beijing, in the People’s Republic of China, this biopharmaceutical entity engages profoundly in the realms of research, development, production, and international marketing of genetic engineering drugs and its related products. Serving not only the domestic market of China but also catering to international demands, the company has established itself as a significant player in the biopharmaceutical sector.
Products and Services
Beijing SL Pharmaceutical Co., Ltd. offers a comprehensive range of formulations and active pharmaceutical ingredients (APIs), catering to various therapeutic areas:
- Temozolomide, Arsenic Trioxide, Lenalidomide Capsules, and More: Focused on oncology, these drugs are essential for treating various cancers.
- Docetaxel, Paclitaxel: Used in chemotherapy treatments to inhibit cancer cell growth.
- Recombinant Proteins (Human Granulocyte Colony-Stimulating Factor, Human Interleukin-11, Human Interleukin-2): These are crucial in enhancing the immune system's functionality, especially in cancer treatment.
- Thymopentin, Vinorelbine Bitartrate: These agents are used for their immune-modulating and anti-cancer properties.
- Recombinant Human Basic Fibroblast Growth Factor, Liraglutide: With applications in regenerative medicine and diabetes management, respectively, showcasing the company's involvement in endocrinology and systemic treatments.
- Insulin Aspart Family: Contributes to diabetes care by providing fast-acting insulin variants.
- Recombinant Human Follitropin(rh-fsh), Ciclosporin: Address reproductive health and immunosuppression, aiding fertility treatments and organ transplant procedures respectively.
- Antivirals and Antibiotics (Adefovir Dipivoxil, Levofloxacin Hydrochloride, Azithromycin): Offering solutions in infectious diseases.
- Anticoagulants and Cardiovascular Drugs (Rivaroxaban, Enoxaparin Sodium, Simvastatin, Telmisartan): Catering to cardiovascular health and thrombotic conditions.
- Ginkgo Biloba Extract, Coenzyme Complex: These supplements support cognitive functions and general wellness.
- Other Specialties (Omeprazole, Ademetionine 1,4-Butanedisulfonate, Glutathione): Encompasses gastrointestinal treatments, liver health supplements, and antioxidant therapies.
Apart from finished formulations, Beijing SL Pharmaceutical Co., Ltd. also specializes in the production of high-quality active pharmaceutical ingredients (APIs), thereby contributing vitally to the pharmaceutical industry's supply chain both domestically and internationally.
Contact Information
Address: Building 1, Bitongyuan, Beijing, China, 100143
Phone: 86 10 6872 7127
Website: https://www.slpharm.com.cn
2025 © Marketlog. All Rights Reserved.
